top of page

Nishant Rastogi, MBA

Vice President, Head of Transactions

Nishant is a healthcare investment professional with over 10 years of experience in finance and life sciences. Nishant joined New Rhein in 2018 and leads the Fund’s Transactions team. He is a founding member of the Philadelphia office.


His responsibilities include identification of new opportunities, due diligence, negotiation and execution of transactions, and portfolio company management. He has directly led assessments and investments in biopharma and medical device companies at various stages of development, across multiple functional areas, and geographies. He is involved in managing New Rhein’s investments in Softhale  (sold to Sino Biopharma), Neuraptive, American Injectables, Butterfly Medical, Saayva, Theranica, and Corsair.


Prior to New Rhein, Nishant was an investor at Broadview Ventures, a mission-driven fund focused on cardiovascular disease. He supported Broadview’s investments in FineHeart, InfoBionic, Apama Medical (sold to Boston Scientific), and Gila Therapeutics, and contributed to a publication in the Journal of the American College of Cardiology on the importance of impact investing in life sciences in 2016.  He serves as an advisor to the Beyond Celiac Foundation, The Parent Project Muscular Dystrophy Foundation, and the 90/10 Institute regarding venture philanthropy and its role in supporting research and development of new medicines.


Nishant began his career at Fidelity Investments. He holds an MBA from Northwestern University, a BA in Economics from Dartmouth College, and has completed postgraduate coursework in medical science from Harvard University.

bottom of page